Symbols / GPCR Stock $47.02 +1.12% Structure Therapeutics Inc.
GPCR (Stock) Chart
About
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Stock Fundamentals
Scroll to Statements| Market Cap | 3.33B | Enterprise Value | 8.44B | Income | -141.20M | Sales | — | Book/sh | 21.41 | Cash/sh | 6.80 |
| Dividend Yield | — | Payout | 0.00% | Employees | 220 | IPO | — | P/E | — | Forward P/E | -25.60 |
| PEG | — | P/S | — | P/B | 2.20 | P/C | — | EV/EBITDA | -45.60 | EV/Sales | — |
| Quick Ratio | 24.43 | Current Ratio | 24.81 | Debt/Eq | 0.43 | LT Debt/Eq | — | EPS (ttm) | -2.40 | EPS next Y | -1.84 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-07 | ROA | -9.39% | ROE | -11.86% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 70.84M | Shs Float | 164.53M | Short Float | 10.83% |
| Short Ratio | 5.66 | Short Interest | — | 52W High | 94.90 | 52W Low | 15.80 | Beta | -1.25 | Avg Volume | 943.63K |
| Volume | 795.60K | Target Price | $109.00 | Recom | Strong_buy | Prev Close | $46.50 | Price | $47.02 | Change | 1.12% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-16 | main | HC Wainwright & Co. | Buy → Buy | $100 |
| 2026-03-02 | main | HC Wainwright & Co. | Buy → Buy | $114 |
| 2026-02-27 | main | Citizens | Market Outperform → Market Outperform | $113 |
| 2026-01-22 | main | JP Morgan | Overweight → Overweight | $105 |
| 2026-01-20 | main | Guggenheim | Buy → Buy | $140 |
| 2025-12-19 | main | HC Wainwright & Co. | Buy → Buy | $90 |
| 2025-12-12 | main | Morgan Stanley | Overweight → Overweight | $125 |
| 2025-12-12 | main | Citizens | Market Outperform → Market Outperform | $120 |
| 2025-12-11 | main | Jefferies | Buy → Buy | $125 |
| 2025-12-09 | main | Citigroup | Buy → Buy | $100 |
| 2025-12-09 | main | Stifel | Buy → Buy | $90 |
| 2025-12-09 | main | Clear Street | Buy → Buy | $99 |
| 2025-08-07 | main | HC Wainwright & Co. | Buy → Buy | $60 |
| 2025-08-07 | main | Guggenheim | Buy → Buy | $90 |
| 2025-08-07 | main | JMP Securities | Market Outperform → Market Outperform | $87 |
| 2025-06-23 | reit | Cantor Fitzgerald | Overweight → Overweight | $65 |
| 2025-06-23 | reit | JMP Securities | Market Outperform → Market Outperform | $89 |
| 2025-05-12 | main | HC Wainwright & Co. | Buy → Buy | $75 |
| 2025-05-02 | init | Citigroup | — → Buy | $60 |
| 2025-04-22 | main | HC Wainwright & Co. | Buy → Buy | $80 |
- [Form 4] Structure Therapeutics Inc. Insider Trading Activity - Stock Titan hu, 23 Apr 2026 20
- Is Structure (GPCR) stock misaligned with fundamentals | Q4 2025: Earnings Fall Short - Balance Sheet - Cổng thông tin điện tử tỉnh Lào Cai hu, 23 Apr 2026 13
- NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now? - Yahoo Finance Mon, 23 Mar 2026 07
- Structure Therapeutics (GPCR) COO & GC Matthew Lang files initial Form 3 - Stock Titan hu, 23 Apr 2026 20
- Discipline and Rules-Based Execution in GPCR Response - Stock Traders Daily ue, 21 Apr 2026 10
- Is Structure Therapeutics (GPCR) Building a Legal-Led Edge in Its Obesity and Metabolic Pipeline Strategy? - simplywall.st Sun, 19 Apr 2026 07
- Structure Therapeutics stock: what’s driving sudden 103% jump in GPCR shares? - TradingView Mon, 08 Dec 2025 08
- GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron - Yahoo Finance ue, 09 Dec 2025 08
- Structure Therapeutics (NASDAQ: GPCR) details 2026 virtual shareholder meeting - Stock Titan hu, 23 Apr 2026 20
- Is Septerna (SEPN) Quietly Redefining Its GPCR Strategy With This First-in-Human SEP-479 Trial? - simplywall.st ue, 21 Apr 2026 17
- Structure Therapeutics (GPCR) Gained from Favorable Clinical Data - Yahoo Finance hu, 19 Feb 2026 08
- Assessing Structure Therapeutics (GPCR) Valuation After Recent Share Price Weakness - Yahoo Finance hu, 09 Apr 2026 07
- Metsera legal chief joins Structure as COO ahead of Phase 3 - Stock Titan ue, 14 Apr 2026 20
- Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why - Yahoo Finance hu, 15 Jan 2026 08
- Assessing Structure Therapeutics (GPCR) Valuation After Positive Phase 2 Data And Large Capital Raise - Yahoo Finance Wed, 14 Jan 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
186.81
+18.06%
|
158.23
+53.96%
|
102.78
+95.53%
|
52.56
|
| Research And Development |
|
225.25
+107.01%
|
108.81
+55.22%
|
70.10
+93.69%
|
36.19
|
| Selling General And Administration |
|
61.55
+24.57%
|
49.41
+51.24%
|
32.67
+99.61%
|
16.37
|
| General And Administrative Expense |
|
61.55
+24.57%
|
49.41
+51.24%
|
32.67
+99.61%
|
16.37
|
| Other Gand A |
|
61.55
+24.57%
|
49.41
+51.24%
|
32.67
+99.61%
|
16.37
|
| Other Operating Expenses |
|
-100.00
|
—
|
—
|
—
|
| Total Expenses |
|
186.81
+18.06%
|
158.23
+53.96%
|
102.78
+95.53%
|
52.56
|
| Operating Income |
|
-186.81
-18.06%
|
-158.23
-53.96%
|
-102.78
-95.53%
|
-52.56
|
| Total Operating Income As Reported |
|
-176.56
-11.59%
|
-158.23
-53.96%
|
-102.78
-95.53%
|
-52.56
|
| EBITDA |
|
-185.48
-17.96%
|
-157.24
-53.43%
|
-102.48
-96.01%
|
-52.28
|
| Normalized EBITDA |
|
-195.72
-24.48%
|
-157.24
-53.43%
|
-102.48
-96.01%
|
-52.28
|
| Reconciled Depreciation |
|
1.33
+34.38%
|
0.99
+236.27%
|
0.29
+6.50%
|
0.28
|
| EBIT |
|
-186.81
-18.06%
|
-158.23
-53.96%
|
-102.78
-95.53%
|
-52.56
|
| Total Unusual Items |
|
10.25
|
0.00
|
0.00
|
—
|
| Total Unusual Items Excluding Goodwill |
|
10.25
|
0.00
|
0.00
|
—
|
| Special Income Charges |
|
10.25
|
0.00
|
0.00
|
—
|
| Net Income |
|
-141.20
-15.24%
|
-122.53
-36.72%
|
-89.62
-74.63%
|
-51.32
|
| Pretax Income |
|
-140.69
-15.11%
|
-122.22
-36.73%
|
-89.38
-74.22%
|
-51.30
|
| Net Non Operating Interest Income Expense |
|
35.87
-0.39%
|
36.01
+168.93%
|
13.39
+965.31%
|
1.26
|
| Net Interest Income |
|
35.87
-0.39%
|
36.01
+168.93%
|
13.39
+965.31%
|
1.26
|
| Other Income Expense |
|
10.25
|
—
|
—
|
—
|
| Tax Provision |
|
0.52
+66.13%
|
0.31
+31.36%
|
0.24
+1288.24%
|
0.02
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
2.15
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-141.20
-15.24%
|
-122.53
-36.72%
|
-89.62
-74.63%
|
-51.32
|
| Net Income From Continuing Operation Net Minority Interest |
|
-141.20
-15.24%
|
-122.53
-36.72%
|
-89.62
-74.63%
|
-51.32
|
| Net Income From Continuing And Discontinued Operation |
|
-141.20
-15.24%
|
-122.53
-36.72%
|
-89.62
-74.63%
|
-51.32
|
| Net Income Continuous Operations |
|
-141.20
-15.24%
|
-122.53
-36.72%
|
-89.62
-74.63%
|
-51.32
|
| Minority Interests |
|
—
|
—
|
—
|
0.00
|
| Normalized Income |
|
-149.30
-21.85%
|
-122.53
-36.72%
|
-89.62
-74.63%
|
-51.32
|
| Net Income Common Stockholders |
|
-141.20
-15.24%
|
-122.53
-36.72%
|
-89.62
-69.62%
|
-52.84
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
0.00
-100.00%
|
1.51
|
| Diluted EPS |
|
—
|
-2.14
+11.98%
|
-2.43
-75.89%
|
-1.38
|
| Basic EPS |
|
—
|
-2.14
+11.98%
|
-2.43
-75.89%
|
-1.38
|
| Basic Average Shares |
|
—
|
57.29
+55.96%
|
36.73
-3.95%
|
38.24
|
| Diluted Average Shares |
|
—
|
57.29
+55.96%
|
36.73
-3.95%
|
38.24
|
| Diluted NI Availto Com Stockholders |
|
-141.20
-15.24%
|
-122.53
-36.72%
|
-89.62
-69.62%
|
-52.84
|
| Gain On Sale Of PPE |
|
10.25
|
0.00
|
0.00
|
—
|
| Net Income From Tax Loss Carryforward |
|
—
|
—
|
—
|
—
|
| Preferred Stock Dividends |
|
—
|
—
|
—
|
1.51
|
| Total Other Finance Cost |
|
-35.87
+0.39%
|
-36.01
-168.93%
|
-13.39
-965.31%
|
-1.26
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
1,583.92
+75.34%
|
903.33
+87.41%
|
482.02
+392.63%
|
97.84
|
| Current Assets |
|
1,570.30
+76.20%
|
891.21
+88.17%
|
473.61
+408.77%
|
93.09
|
| Cash Cash Equivalents And Short Term Investments |
|
1,446.20
+63.69%
|
883.52
+89.06%
|
467.32
+414.44%
|
90.84
|
| Cash And Cash Equivalents |
|
799.62
+371.73%
|
169.51
+30.60%
|
129.79
+397.46%
|
26.09
|
| Other Short Term Investments |
|
646.57
-9.44%
|
714.01
+111.54%
|
337.53
+421.28%
|
64.75
|
| Receivables |
|
100.00
|
0.00
|
—
|
—
|
| Other Receivables |
|
100.00
|
—
|
—
|
—
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
24.11
+213.35%
|
7.69
+22.40%
|
6.29
+179.58%
|
2.25
|
| Total Non Current Assets |
|
13.62
+12.34%
|
12.12
+44.12%
|
8.41
+76.81%
|
4.76
|
| Net PPE |
|
12.90
+83.92%
|
7.01
-16.15%
|
8.36
+546.87%
|
1.29
|
| Gross PPE |
|
15.87
+83.45%
|
8.65
-3.99%
|
9.01
+448.60%
|
1.64
|
| Accumulated Depreciation |
|
-2.97
-81.48%
|
-1.64
-154.04%
|
-0.64
-84.53%
|
-0.35
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
1.50
+101.21%
|
0.75
+35.14%
|
0.55
+219.08%
|
0.17
|
| Construction In Progress |
|
1.28
|
0.00
|
—
|
—
|
| Other Properties |
|
11.55
+76.56%
|
6.54
-7.79%
|
7.10
+421.76%
|
1.36
|
| Leases |
|
1.54
+12.94%
|
1.36
+0.00%
|
1.36
+1147.71%
|
0.11
|
| Other Non Current Assets |
|
0.72
-85.96%
|
5.11
+11246.67%
|
0.04
-98.70%
|
3.46
|
| Total Liabilities Net Minority Interest |
|
67.54
+75.49%
|
38.49
+32.48%
|
29.05
-86.36%
|
212.99
|
| Current Liabilities |
|
63.28
+75.69%
|
36.02
+45.60%
|
24.74
+90.16%
|
13.01
|
| Payables And Accrued Expenses |
|
47.97
+77.46%
|
27.03
+42.47%
|
18.98
+106.12%
|
9.21
|
| Payables |
|
13.86
+72.78%
|
8.02
+69.21%
|
4.74
-23.31%
|
6.18
|
| Accounts Payable |
|
13.86
+72.78%
|
8.02
+69.21%
|
4.74
-21.09%
|
6.01
|
| Other Payable |
|
—
|
—
|
—
|
—
|
| Current Accrued Expenses |
|
34.11
+79.44%
|
19.01
+33.56%
|
14.23
+370.82%
|
3.02
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
12.43
+70.56%
|
7.29
+68.55%
|
4.33
+22.04%
|
3.54
|
| Total Tax Payable |
|
—
|
—
|
0.36
+104.60%
|
0.17
|
| Income Tax Payable |
|
—
|
—
|
0.36
+104.60%
|
0.17
|
| Current Debt And Capital Lease Obligation |
|
2.88
+69.49%
|
1.70
+17.92%
|
1.44
+453.85%
|
0.26
|
| Current Capital Lease Obligation |
|
2.88
+69.49%
|
1.70
+17.92%
|
1.44
+453.85%
|
0.26
|
| Total Non Current Liabilities Net Minority Interest |
|
4.26
+72.59%
|
2.47
-42.80%
|
4.31
-97.84%
|
199.97
|
| Long Term Debt And Capital Lease Obligation |
|
3.61
+66.77%
|
2.16
-46.08%
|
4.01
|
0.00
|
| Long Term Capital Lease Obligation |
|
3.61
+66.77%
|
2.16
-46.08%
|
4.01
|
0.00
|
| Other Non Current Liabilities |
|
0.65
+114.24%
|
0.30
+1.34%
|
0.30
|
—
|
| Preferred Securities Outside Stock Equity |
|
—
|
0.00
|
0.00
-100.00%
|
199.97
|
| Stockholders Equity |
|
1,516.38
+75.34%
|
864.84
+90.93%
|
452.97
+493.40%
|
-115.14
|
| Common Stock Equity |
|
1,516.38
+75.34%
|
864.84
+90.93%
|
452.97
+493.40%
|
-115.14
|
| Capital Stock |
|
0.02
+23.53%
|
0.02
+21.43%
|
0.01
+1300.00%
|
0.00
|
| Common Stock |
|
0.02
+23.53%
|
0.02
+21.43%
|
0.01
+1300.00%
|
0.00
|
| Preferred Stock |
|
—
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
212.51
+23.65%
|
171.86
+23.44%
|
139.22
+21.35%
|
114.73
|
| Ordinary Shares Number |
|
212.51
+23.65%
|
171.86
+23.44%
|
139.22
+21.35%
|
114.73
|
| Additional Paid In Capital |
|
1,985.60
+66.44%
|
1,193.01
+81.03%
|
659.00
+34205.21%
|
1.92
|
| Retained Earnings |
|
-470.30
-42.91%
|
-329.10
-59.31%
|
-206.57
-76.63%
|
-116.95
|
| Gains Losses Not Affecting Retained Earnings |
|
1.05
+15.32%
|
0.91
+75.43%
|
0.52
+573.64%
|
-0.11
|
| Other Equity Adjustments |
|
1.05
+15.32%
|
0.91
+75.43%
|
0.52
+573.64%
|
-0.11
|
| Total Equity Gross Minority Interest |
|
1,516.38
+75.34%
|
864.84
+90.93%
|
452.97
+493.40%
|
-115.14
|
| Total Capitalization |
|
1,516.38
+75.34%
|
864.84
+90.93%
|
452.97
+493.40%
|
-115.14
|
| Working Capital |
|
1,507.02
+76.22%
|
855.19
+90.52%
|
448.87
+460.53%
|
80.08
|
| Invested Capital |
|
1,516.38
+75.34%
|
864.84
+90.93%
|
452.97
+493.40%
|
-115.14
|
| Total Debt |
|
6.49
+67.97%
|
3.86
-29.18%
|
5.45
+1997.31%
|
0.26
|
| Capital Lease Obligations |
|
6.49
+67.97%
|
3.86
-29.18%
|
5.45
+1997.31%
|
0.26
|
| Net Tangible Assets |
|
1,516.38
+75.34%
|
864.84
+90.93%
|
452.97
+493.40%
|
-115.14
|
| Tangible Book Value |
|
1,516.38
+75.34%
|
864.84
+90.93%
|
452.97
+493.40%
|
-115.14
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-222.20
-90.51%
|
-116.64
-46.73%
|
-79.49
-72.35%
|
-46.12
|
| Cash Flow From Continuing Operating Activities |
|
-222.20
-90.51%
|
-116.64
-46.73%
|
-79.49
-72.35%
|
-46.12
|
| Net Income From Continuing Operations |
|
-141.20
-15.24%
|
-122.53
-36.72%
|
-89.62
-74.63%
|
-51.32
|
| Depreciation Amortization Depletion |
|
1.33
+34.38%
|
0.99
+236.27%
|
0.29
+6.50%
|
0.28
|
| Depreciation |
|
1.33
+34.38%
|
0.99
+236.27%
|
0.29
+6.50%
|
0.28
|
| Depreciation And Amortization |
|
1.33
+34.38%
|
0.99
+236.27%
|
0.29
+6.50%
|
0.28
|
| Other Non Cash Items |
|
2.56
+59.25%
|
1.60
+145.04%
|
0.66
+88.76%
|
0.35
|
| Stock Based Compensation |
|
28.99
+54.26%
|
18.79
+129.45%
|
8.19
+225.82%
|
2.51
|
| Operating Gains Losses |
|
-10.25
|
—
|
—
|
—
|
| Gain Loss On Investment Securities |
|
-10.25
|
—
|
—
|
—
|
| Change In Working Capital |
|
-88.04
-3070.34%
|
2.96
-57.45%
|
6.97
+134.70%
|
2.97
|
| Change In Receivables |
|
-100.00
|
0.00
|
0.00
|
—
|
| Change In Prepaid Assets |
|
-16.41
-1065.70%
|
-1.41
+65.12%
|
-4.04
-1223.61%
|
-0.30
|
| Change In Payables And Accrued Expense |
|
26.28
+138.38%
|
11.02
-2.47%
|
11.30
+205.98%
|
3.69
|
| Change In Accrued Expense |
|
21.51
+178.79%
|
7.72
-36.55%
|
12.16
+689.29%
|
1.54
|
| Change In Payable |
|
4.76
+44.09%
|
3.31
+484.53%
|
-0.86
-139.94%
|
2.15
|
| Change In Account Payable |
|
4.76
+44.09%
|
3.31
+484.53%
|
-0.86
-139.94%
|
2.15
|
| Change In Other Current Assets |
|
4.39
+186.72%
|
-5.06
-33840.00%
|
0.01
+125.00%
|
-0.06
|
| Change In Other Current Liabilities |
|
-2.30
-44.31%
|
-1.59
-405.08%
|
-0.32
+12.74%
|
-0.36
|
| Investing Cash Flow |
|
89.80
+125.02%
|
-358.91
-33.75%
|
-268.34
-332.06%
|
-62.11
|
| Cash Flow From Continuing Investing Activities |
|
89.80
+125.02%
|
-358.91
-33.75%
|
-268.34
-332.06%
|
-62.11
|
| Net PPE Purchase And Sale |
|
-3.61
-180.16%
|
-1.29
+40.47%
|
-2.17
-1298.06%
|
-0.15
|
| Purchase Of PPE |
|
-3.61
-180.16%
|
-1.29
+40.47%
|
-2.17
-1298.06%
|
-0.15
|
| Capital Expenditure |
|
-3.61
-180.16%
|
-1.29
+40.47%
|
-2.17
-1298.06%
|
-0.15
|
| Net Investment Purchase And Sale |
|
93.41
+126.12%
|
-357.62
-34.35%
|
-266.18
-329.64%
|
-61.95
|
| Purchase Of Investment |
|
-547.38
+22.08%
|
-702.52
-68.33%
|
-417.36
-238.07%
|
-123.45
|
| Sale Of Investment |
|
640.79
+85.79%
|
344.90
+128.14%
|
151.18
+145.82%
|
61.50
|
| Financing Cash Flow |
|
762.52
+47.99%
|
515.26
+14.11%
|
451.53
+1456.25%
|
29.01
|
| Cash Flow From Continuing Financing Activities |
|
762.52
+47.99%
|
515.26
+14.11%
|
451.53
+1456.25%
|
29.01
|
| Net Common Stock Issuance |
|
665.71
+29.37%
|
514.57
+8.95%
|
472.30
|
0.00
|
| Proceeds From Stock Option Exercised |
|
99.45
+3900.24%
|
2.49
+210.75%
|
0.80
+2324.24%
|
0.03
|
| Net Other Financing Charges |
|
-2.64
-46.88%
|
-1.80
+91.67%
|
-21.57
-756.09%
|
-2.52
|
| Changes In Cash |
|
630.11
+1486.47%
|
39.72
-61.70%
|
103.70
+230.91%
|
-79.21
|
| Beginning Cash Position |
|
169.51
+30.60%
|
129.79
+397.46%
|
26.09
-75.22%
|
105.31
|
| End Cash Position |
|
799.62
+371.73%
|
169.51
+30.60%
|
129.79
+397.46%
|
26.09
|
| Free Cash Flow |
|
-225.81
-91.49%
|
-117.93
-44.42%
|
-81.66
-76.46%
|
-46.27
|
| Amortization Of Securities |
|
-15.59
+15.59%
|
-18.46
-209.04%
|
-5.97
-560.22%
|
-0.91
|
| Common Stock Issuance |
|
665.71
+29.37%
|
514.57
+8.95%
|
472.30
|
0.00
|
| Issuance Of Capital Stock |
|
665.71
+29.37%
|
514.57
+8.95%
|
472.30
+1399.35%
|
31.50
|
| Net Preferred Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
31.50
|
| Preferred Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
31.50
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-23 View
- 42026-04-16 View
- 8-K2026-04-15 View
- 42026-03-23 View
- 42026-03-23 View
- 42026-03-23 View
- 42026-03-23 View
- 42026-03-23 View
- 42026-03-23 View
- 8-K2026-03-16 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-03-05 View
- 10-K2026-02-26 View
- 8-K2026-02-26 View
- 42026-01-20 View
- 8-K2026-01-05 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|